StemMed is a pharmaceutical development and testing company located in Houston, Texas that seeks to advance the treatment of breast cancer through novel insights into the biology of the stem cells that cause the disease. We now understand that only a small subset of the heterogeneous cells within a malignant tumor are responsible for the initiation and maintenance of tumor growth. Therefore, we believe that specifically targeting such cells for therapeutic intervention will inhibit tumor formation, growth and metastasis. We also believe that this approach may be particularly effective in the treatment of cancers that are resistant to conventional therapies.